Paid Atopic Dermatitis Clinical Trials
Eczema clinical trials now enrolling. Access new biologics and JAK inhibitors. Compensation up to $3,200 for adults and adolescents with moderate-to-severe AD.
Compensation
$1,500 - $3,200
Duration
16-52 weeks
Phase
Phase II/III
FDA Regulated
IRB Approved
GCP Certified
Who May Qualify
- Age 12-75 years (adolescent and adult studies available)
- Chronic atopic dermatitis for at least 1 year
- Moderate-to-severe disease (IGA ≥3, EASI ≥16, BSA ≥10%)
- Inadequate response to topical corticosteroids
- Candidate for systemic therapy
- Willing to avoid excessive sun exposure
Who May Not Qualify
- Other inflammatory skin conditions (psoriasis, contact dermatitis)
- Active skin infection requiring treatment
- Prior use of specific biologics (study-dependent)
- Immunocompromised state
- Use of systemic immunosuppressants within washout period
Frequently Asked Questions
What eczema treatments are being studied?
+
Current trials include new IL-13 and IL-31 blockers, oral JAK inhibitors, and novel topical therapies. Studies are available for patients with different treatment histories and severity levels.
How is eczema severity measured?
+
Disease severity is assessed using standardized tools including EASI (Eczema Area and Severity Index), IGA (Investigator Global Assessment), and measurement of affected body surface area. Itch intensity is also tracked.
Can I use moisturizers during the study?
+
Yes, regular moisturizer use is typically encouraged and may be required. The study will provide specific guidance on permitted topical products.
Are there studies for children with eczema?
+
Yes, pediatric studies are available for children as young as 6 months in some cases. Adolescent studies (ages 12-17) are also commonly recruiting.